Literature DB >> 27079806

The role of miRNAs and epigenetic mechanisms in primary gastric mucosa-associated lymphoid tissue lymphoma.

Diamantina Vasilatou1, Athanasios D Sioulas1, Vasiliki Pappa1, Ioannis S Papanikolaou1, Konstantinos Triantafyllou1, George D Dimitriadis1, Sotirios G Papageorgiou1.   

Abstract

Gastric mucosa-associated lymphoid tissue (MALT) lymphoma is a rare low-grade B-cell non-Hodgkin lymphoma associated with Helicobacter pylori infection and the subsequent chronic inflammation. Significant progress in understanding the pathogenesis of the disease has already been made. However, the exact molecular pathways of lymphomagenesis remain unclear. Furthermore, difficulties regarding accurate diagnosis of gastric MALT lymphoma and its discrimination from gastritis or other lymphoma subtypes arise. Recent studies evaluate the role of miRNAs and epigenetic alterations on MALT lymphoma pathogenesis and prognosis. This review critically summarizes the most important data on the role of miRNAs and epigenetics in MALT lymphomas pathogenesis, prognosis and treatment.

Entities:  

Keywords:  MALT; epigenetics; miRNAs

Mesh:

Substances:

Year:  2016        PMID: 27079806     DOI: 10.2217/fon-2016-0038

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  3 in total

1.  Clinical manifestations and epigenetic mechanisms of gastric mucosa associated lymphoid tissue lymphoma and long-term follow-up following Helicobacter pylori eradication.

Authors:  Yan Song; Kui Jiang; Shuai Su; Bangmao Wang; Guangxia Chen
Journal:  Exp Ther Med       Date:  2017-11-01       Impact factor: 2.447

Review 2.  Deciphering splenic marginal zone lymphoma pathogenesis: the proposed role of microRNA.

Authors:  Jacob E Robinson; Christine E Cutucache
Journal:  Oncotarget       Date:  2018-07-06

3.  Deregulation of miRNA in Helicobacter pylori-Induced Gastric MALT Lymphoma: From Mice to Human.

Authors:  Alice Blosse; Michael Levy; Cyrielle Robe; Cathy Staedel; Christiane Copie-Bergman; Philippe Lehours
Journal:  J Clin Med       Date:  2019-06-13       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.